New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
ARKG ETF · ARK Genomic Revolution ETF
The ARKG Exchange Traded Fund (ETF) is provided by Ark Investment. This fund is actively managed; it does not track an index. This share class generates a stream of income by distributing dividends.
Last update Today at 1:30 PM UTC
LIVE
CLOSED
This fund is part ofBioTech & Genomics1M perf.+15.13%
Last price
$29.78
1M perf.
+15.42%
1M flows
-€42M
AuM
€986M
E/R
0.75%
Rating
Not rated
ESG Consensus®
ARKG
$29.78
Performance & flows
Segment for quartile rank
January 21, 2026 → April 21, 2026
Create a free account to view the flows graph
ARKG
$30.74
-5.15%
BioTech & Genomics
-3.76%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +15.42%  | -5.15%  | +50.23% | +0.42%  | -64.94% | +16.17% | +16.17% | +5.28%  | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
4/21/2026
$30.74
1D NAV change
-1.68%
Dividend policy
No. of holdings
27
Inception date
4/2/2019
Jurisdiction
United States
Distribution
United States
Legal structure
Open-end Management Investment Company
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialSimilar ETFs in your region
PSCH
1M perf.
+10.74%
E/R
0.29%
XBI
1M perf.
+12.81%
E/R
0.35%
CURE
1M perf.
+10.21%
E/R
0.45%
AAKG
1M perf.
+16.60%
E/R
0.75%
PTH
1M perf.
+13.34%
E/R
0.72%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -5.15% | +50.23% | +0.42% | -64.94% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
USA
70.40%
Switzerland
9.23%
Netherlands
1.42%
Unavailable
18.95%
Sectors
Health Care
78.38%
Information Technology
1.10%
Unavailable
20.52%
Diversification
Total weight of top 15 holdings out of 27
Top 15 holdings
Data as of March 31, 2026
CRISPR THERAPEUTICS
10X GENOMICS INC
BEAM THERAPEUTICS
PERSONALIS INC
NATERA
ILLUMINA
GUARDANT HEALTH INC
INTELLIA THERAPEUTICS INC
Create a free account to view top holdings
CAREDX INC/D
RECURSION PHARMACEUTICALS
ABSCI
VERACYTE INC/D
ADAPTIVE BIOTECHNOLOGIES
NURIX THERAPEUTICS
SEMA4 HOLDINGS CORP
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Issuer
Ark Investment
Ark Investment ID Card
Number of funds
11
Total AuM
€11.88B
Expense ratio range
0.49% - 0.89%
Average expense ratio
0.7582%
Top 5 funds by Ark Investment
| AuM | ||
|---|---|---|
ARKK | ARK Innovation ETF | €6B |
ARKQ | ARK Autonomous Technology & Robotics ETF | €1.83B |
ARKW | ARK Next Generation Internet ETF | €1.42B |
ARKG | ARK Genomic Revolution ETF | €986M |
ARKX | ARK Space & Defense Innovation ETF | €732M |
Frequently asked questions about ARKG
What does ARK Genomic Revolution ETF, ARKG, invest in?
ARKG is a Active ETF. This ETF provides exposure to Other Equities.
What is the Total Expense ratio (TER) of ARKG?
ARKG carries a total expense ratio (TER) of 0.75%, indicating the annual cost for holding the fund.
When was ARKG launched?
ARKG was introduced to the market on April 2, 2019. It trades on United States
Who is the ETF issuer of ARKG?
ARK Genomic Revolution ETF, ARKG, is provided by Ark Investment. Learn more about Ark Investment here.
What is the current assets under management (AUM) of ARKG?
ARKG oversees €986M in assets as of April 21, 2026.
How has ARKG performed lately?
Based on data from April 21, 2026, ARKG returned 15.42% over the past month, -5.15% over the last three months and 5.28% year-to-date.
What are the latest inflows or outflows for ARKG?
As of April 21, 2026, ARKG recorded net flows of -€42M over the last month and -€68M year-to-date.
Does ARKG distribute dividends?
ARKG follows a distributing dividend policy, meaning it pays out income to investors.
What are the main country or region exposures of ARKG?
As of March 31, 2026, ARKG has significant geographic allocations in USA, Switzerland and Netherlands.
In which sector or theme does ARKG invest in?
As of March 31, 2026, ARKG focuses largely on Health Care and Information Technology.
How many securities does ARKG hold and how diversified is it?
As of March 31, 2026, ARKG holds 27 positions in its portfolio, with 62.50% of assets concentrated in its top 15 holdings.
What are the main positions in ARKG?
As of March 31, 2026, ARKG top three holdings include CRISPR THERAPEUTICS, 10X GENOMICS INC and BEAM THERAPEUTICS.
What is the base currency of ARKG?
The base currency of ARKG is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
